Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03362112

Enrollment

1713

Registered

2017-12-05

Start date

2015-01-30

Completion date

2017-06-01

Last updated

2022-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Keywords

lipoprotein-associated phospholipase A2

Brief summary

Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).

Detailed description

The investigators recorded clinical factors, serum levels of glucose, HbA1c, lipids and LP-PLA2 in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016. The relationship between levels of LP-PLA2 and diabetic complications are analysed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.

Exclusion criteria

1. Patients use systemic steroidal anti-inflammatory drugs. 2. Patients are pregnant. 3. Patients with an acute infection.

Design outcomes

Primary

Measure	Time frame	Description
Lipoprotein-associated Phospholipase A2	Day one	the plasma lipoprotein-associated phospholipase A2 level of patients

Secondary

Measure	Time frame	Description
HbA1c	Day one	the glycosylated hemoglobin level of patients
LDL-c	Day one	low density lipoprotein cholesterol
Diabetic Complication	Day one	the prevalence of atherosclerosis, diabetic Nephropathy, diabetic retinopathy and diabetic neuropathy
C Peptide	Day one	fast and 120min postprandial C peptide

Participant flow

Participants by arm

Arm	Count
Patients With T2DM Patients with type 2 diabetes	1,713
Total	1,713

Baseline characteristics

Characteristic	Patients With T2DM	—
Age, Continuous	58.5 years STANDARD_DEVIATION 12.5	—
Race and Ethnicity Not Collected	—	— Participants
Region of Enrollment China	1713 Participants	—
Sex: Female, Male Female	658 Participants	—
Sex: Female, Male Male	1055 Participants	—

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	0 / 0
serious Total, serious adverse events	0 / 0

Outcome results

Primary